VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 7, 2026
Stock Comparison
Gilead Sciences, Inc. vs The Progressive Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisThe Progressive Corporation
PGR · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into The Progressive Corporation's moat claims, evidence, and risks.
View PGR analysisComparison highlights
- Moat score gap: The Progressive Corporation leads (75 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); The Progressive Corporation has 2 segments (85% in Personal Lines).
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; The Progressive Corporation has 5 across 2.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
The Progressive Corporation
Personal Lines
U.S. private passenger auto insurance (dominant) plus specialty personal lines and homeowners/renters (small portion)
United States
Individuals/households
Primary insurer (P&C)
85%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
The Progressive Corporation strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
The Progressive Corporation segments
Full profile >Personal Lines
Oligopoly
Commercial Lines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.